Please note that a publication can be assigned to several endpoints, i.e. the sum of publications from the individual thematic points and subpoints can be greater than the total sum of actual publications.
Authors | Year | Exposed system | Parameters | Magnetic flux density/field strength |
---|---|---|---|---|
Buldak RJ et al. | 2012 | intact cell/cell culture, AT478 (murine squamous cell carcinoma cells) | magnetic field, low frequency, 50/60 Hz, co-exposure | 1 mT |
Morabito C et al. | 2010 | intact cell/cell culture, C2C12 cells (undifferentiated myoblasts and differentiated myotubes) | magnetic field, low frequency, 50/60 Hz | 0.1–1 mT |
Eleuteri AM et al. | 2009 | intact cell/cell culture, Caco 2 cells (human colon adenocarcinoma cell line) | magnetic field, low frequency, 50/60 Hz, power transmission line | 1 mT |
Cios A et al. | 2021 | intact cell/cell culture, HEK293 (kidney cells), 786-O, 769-P, and Caki1 (clear cell renal carcinoma cell lines) | magnetic field, 50/60 Hz | 4.5 mT |
Duong CN et al. | 2016 | intact cell/cell culture, HMO6 cells (human microglial cell line) | magnetic field, low frequency, 50/60 Hz, co-exposure | 0.01–1 mT |
Palumbo R et al. | 2006 | intact cell/cell culture, Jurkat cells (T lymphocyte hybridoma cell line) | magnetic field, 50/60 Hz, power transmission line, co-exposure | 1 mT |
Garip AI et al. | 2010 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, low frequency, 50/60 Hz | 1 mT |
Mannerling AC et al. | 2010 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, low frequency, 50/60 Hz | 0.025–0.1 mT |
Ayse IG et al. | 2010 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, low frequency, 50/60 Hz, co-exposure | 5 mT |
Brisdelli F et al. | 2014 | intact cell/cell culture, K562 cells (human erythroleukemic cell line) | magnetic field, 50/60 Hz, co-exposure | 0.01–2 mT |
This website uses cookies to provide you the best browsing experience. By continuing to use this website you accept our use of cookies.